Related Experiment Videos
Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction
H Fretz1, P Furet, C Garcia-Echeverria
1Oncology Research, Novartis Pharma Inc., Basel, CH-4002, Switzerland. heinz.fretz@pharma.novartis.com
Abstract:
Receptor protein tyrosine kinases are usually activated upon binding their growth factors, or other suitable ligands, to their extracellular domains. These activated receptors initiate cytoplasmic signalling cascades which, when aberrant, can result in different disease states, such as oncogenic transformation. Many receptor protein tyrosine kinases use Src homology 2 domains (SH2) to couple growth factor activation with intracellular signalling pathways to mediate cell control and other biological events. The characterization of the components involved in these signal transduction pathways has resulted in the identification of new attractive targets for therapeutic intervention. Such is the case for the protein-protein interactions involving the SH2 domain of growth factor receptor bound protein 2 (Grb2). Agents that specifically disrupt Grb2-SH2 binding interactions involved in aberrant signalling could potentially shut down these oncogenic pathways and thus block human malignancies. This paper reviews the structural characteristics of the Grb2-SH2 domain and the approaches which have been used to identify antagonists of the Grb2-SH2 domain. Examples have been selected from our own research to illustrate how the unique structural features of the ligand-bound Grb2-SH2 have been exploited to design potent and selective Grb2-SH2 antagonists.
Insights
Targeting the Grb2-SH2 domain offers a novel therapeutic strategy against cancer. Disrupting these protein interactions can halt oncogenic pathways, blocking human malignancies by inhibiting aberrant signaling.
Area of Science:
- Molecular Biology
- Biochemistry
- Oncology
Background:
- Receptor protein tyrosine kinases (RTKs) activate signaling cascades upon ligand binding, influencing cell control.
- Aberrant RTK signaling is implicated in oncogenic transformation and various disease states.
- Src homology 2 (SH2) domains are crucial for coupling RTK activation to intracellular signaling pathways.
Purpose of the Study:
- To review the structural characteristics of the Grb2-SH2 domain.
- To explore approaches for identifying antagonists of the Grb2-SH2 domain.
- To illustrate the design of potent and selective Grb2-SH2 antagonists based on structural features.
Main Methods:
- Structural characterization of the Grb2-SH2 domain.
- Identification of protein-protein interaction inhibitors.
- Structure-based drug design of Grb2-SH2 antagonists.
Main Results:
- The Grb2-SH2 domain plays a key role in mediating growth factor signaling.
- Specific disruption of Grb2-SH2 binding interactions can inhibit oncogenic pathways.
- Exploitation of unique structural features of ligand-bound Grb2-SH2 enables antagonist design.
Conclusions:
- Targeting the Grb2-SH2 domain represents a promising therapeutic strategy for human malignancies.
- Development of selective Grb2-SH2 antagonists can effectively block aberrant oncogenic signaling.
- Structure-guided design is effective in creating potent inhibitors of critical protein-protein interactions.